Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-beta1

Endocrinology. 2003 Oct;144(10):4280-4. doi: 10.1210/en.2003-0554. Epub 2003 Jul 24.

Abstract

In a preliminary study, we observed that TGF-beta1 induced both proliferation and growth arrest in prostatic stromal cells, depending on the concentration of TGF-beta1 used in the culture medium. In this study, we explored possible mechanisms of this dual effect of TGF-beta. Primary cultures of prostatic stromal cells, established from clinical surgical specimens and treated with low doses of TGF-beta1 (0.001-0.01 ng/ml), resulted in an increase in cell proliferation. The addition of neutralizing antibody against platelet-derived growth factor (PDGF)-BB, but not anti-PDGF-AA, abrogated this stimulatory effect of TGF-beta1. TGF-beta1 treatment resulted in a dose-related increase in PDGF-BB production as measured by ELISA. Cells underwent growth arrest at high concentrations of TGF-beta1 (1.0 and 10 ng/ml). An inhibitor of cyclin-dependent kinase (cdk), p15INK4b, was up-regulated at both transcript and protein levels in these cultures by TGF-beta1 in a dose-related manner as determined by RT-PCR and Western blot analysis. The transcript, but not the protein, for another cdk inhibitor, p21Cip1, was up-regulated with treatment of TGF-beta1 to these cells. Levels of other cdk inhibitors, such as p16INK4a and p27Kip1, were constitutively expressed in prostatic stromal cells and were not significantly affected by TGF-beta1 treatment. Finally, the growth arrest effect of TGF-beta1 was abrogated when antisense oligonucleotides to p15INH4b, but not p21Cip1, were added to the culture medium. These data indicate that the dual effect of TGF-beta1 is mediated, at least, by up-regulation of PDGF-BB and p15INK4b, respectively.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies / pharmacology
  • Becaplermin
  • Blotting, Western
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism
  • Cell Division / drug effects
  • Cells, Cultured
  • Culture Media
  • Cyclin-Dependent Kinase Inhibitor p15
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclin-Dependent Kinases / antagonists & inhibitors
  • Cyclins / metabolism
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / metabolism
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Male
  • Oligonucleotides, Antisense / administration & dosage
  • Platelet-Derived Growth Factor / biosynthesis
  • Platelet-Derived Growth Factor / immunology
  • Prostate / cytology*
  • Prostate / metabolism
  • Proto-Oncogene Proteins c-sis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Stromal Cells / cytology*
  • Stromal Cells / metabolism
  • Thymidine / metabolism
  • Transforming Growth Factor beta / administration & dosage
  • Transforming Growth Factor beta / pharmacology*
  • Transforming Growth Factor beta1
  • Tumor Suppressor Proteins*
  • Up-Regulation

Substances

  • Antibodies
  • CDKN1A protein, human
  • CDKN2B protein, human
  • Cell Cycle Proteins
  • Culture Media
  • Cyclin-Dependent Kinase Inhibitor p15
  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • Enzyme Inhibitors
  • Oligonucleotides, Antisense
  • Platelet-Derived Growth Factor
  • Proto-Oncogene Proteins c-sis
  • TGFB1 protein, human
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • Tumor Suppressor Proteins
  • Becaplermin
  • Cyclin-Dependent Kinases
  • Thymidine